BRISTOL-MYERS SQUIBB's DOVONEX (CALCIPOTRIENE) IMPROVES MODERATE PLAQUE PSORIASIS IN 70% OF PATIENTS AFTER EIGHT WEEKS; OINTMENT APPROVED BY FDA DEC. 29
Executive Summary
Bristol-Myers Squibb's Dovonex (calcipotriene) ointment improves moderate plaque psoriasis in approximately 70% of patients after eight weeks of therapy, approved labeling states.